INOVIO's Pan-SARS-CoV-2 vaccine candidate INO-4802 is not matched to a single variant, unlike other variant vaccines in development; INO-4802 could potentially offer broader immune responsesPhase 1/2 clinical trials with INO-4802 are planned this yearINOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that its next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant) in preclinical models. These...